Statement of Changes in Beneficial Ownership (4)
September 09 2016 - 11:50AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Aurigene Discovery Technologies Ltd
|
2. Issuer Name
and
Ticker or Trading Symbol
CURIS INC
[
CRIS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
39-40, KIADB INDUSTRIAL AREA,, PHASE II, ELECTRONIC CITY HOSUR ROAD
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/18/2015
|
(Street)
BANGALORE, KARNATAKA, K7 560100
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, par value $0.01 per share
|
9/7/2016
|
9/7/2016
|
P
|
|
10208333
|
A
|
$2.40
|
27328464
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
Remarks:
Aurigene Discovery Technologies Limited ("Aurigene") has acquired from the Issuer an additional 10,208,333 shares of Common Stock, par value $0.01 per share, of the Issuer at a purchase price of $2.40 per share.
1. This Form 4 is being filed jointly by (i) Aurigene Discovery Technologies Limited ("Aurigene"), which (after giving effect to the acquisition of an additional 10,208,333 shares as described above) directly holds 27,328,464 shares of Common Stock of the Issuer (the "Reported Securities"), (ii) Dr. Reddy's Laboratories Ltd. ("DRL"), as the parent company and 100% owner of Aurigene, and (iii) Dr. Reddy's Holdings Ltd. ("DRHL"), in the event that it could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL.
2. In the event that DRHL could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL, its proportional pecuniary interest in such Reported Securities would be approximately 24.262%, which would represent approximately 6,630,545 shares of Common Stock of the Issuer.
3. The filing of this Form 4 shall not be deemed an admission for the purposes of Section 16 or any other purpose that any reporting person is the beneficial owner of any Reported Securities, and DRHL expressly disclaims that it is the beneficial owner of any of the Reported Securities.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Aurigene Discovery Technologies Ltd
39-40, KIADB INDUSTRIAL AREA,
PHASE II, ELECTRONIC CITY HOSUR ROAD
BANGALORE, KARNATAKA, K7 560100
|
|
X
|
|
|
DR REDDYS LABORATORIES LTD
8-2-337, ROAD NO. 3, BANJARA HILLS
HYDERABAD, TELANGANA, K7 500 034
|
|
X
|
|
|
Dr. Reddy's Holdings Ltd
7-1-27, AMEERPET
HYDERABAD, TELANGANA, K7 500 016
|
|
X
|
|
|
Signatures
|
AURIGENE DISCOVERY TECHNOLOGIES LIMITED, By: /s/ Ashish Lath, Name: Ashish Lath, Title: Director of Finance
|
|
9/8/2016
|
**
Signature of Reporting Person
|
Date
|
DR. REDDY'S LABORATORIES LIMITED, By: /s/ Saumen Chakraborty, Name: Saumen Chakraborty, Title: President and Chief Financial Officer
|
|
9/8/2016
|
**
Signature of Reporting Person
|
Date
|
DR. REDDY'S HOLDINGS LIMITED, By:/s/ G V Prasad, Name: G V Prasad, Title: Director
|
|
9/8/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2024 to May 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From May 2023 to May 2024